Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adherence and patient experience with capecitabine in daily oncology practice
NL-OMON36444Active, not recruiting
- Sponsor
- Vrije University Medical Center
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of capecitabine in colorectal cancer (CRC), gastric cancer (GC) and breast cancer, sponsored by Vrije University Medical Center. Primary endpoint: Adherence rate. Started Feb 2010; status: active, not recruiting.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)breast cancer
Beyond the preview
Go deeper on NL-OMON36444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36444.